Dermatology World October 2011 : Page-3
give your patients the potency they need LUXÍQ Foam—when you need a medium-potency steroid for corticosteroid-responsive scalp dermatoses LUXÍQ Foam is a medium-potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. A phase 3, double-blind, randomized study demonstrated non-inferiority of LUXÍQ Foam to betamethasone valerate lotion (superiority comparison not permitted) and superiority of LUXÍQ Foam to vehicle foam. Achievement of Investigator’s Global Assessment score of clear or almost clear of scalp psoriasis within 28 days — 67% (n=43) of patients treated with LUXÍQ Foam — 46% (n=29) of patients treated with a betamethasone valerate lotion — 19% (n=6) of patients treated with vehicle foam SCALP DERMATITIS: 28-DAY TRIAL BASELINE BEFORE LUXÍQ FOAM. AFTER 28 DAYS OF LUXÍQ FOAM BID TREATMENT. (INDIVIDUAL RESULTS MAY VARY) The potency they need delivered in VersaFoam ® Technology VersaFoam-HF ® Hydroethanolic Formulation Disappears rapidly at skin temperature (90°F-95°F)—leaving minimal residue Neither hydrating nor drying Free of fragrance, preservatives, and parabens Non-staining IMPORTANT SAFETY INFORMATION Systemic absorption of topical corticosteroids has caused reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insuf ciency after withdrawal of treatment If irritation develops, LUXÍQ Foam should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation, as with most topical products not containing corticosteroids Safety and ef cacy in pediatric patients have not been established In clinical studies, the most common adverse events associated with the use of LUXÍQ Foam were burning, stinging, or itching at the application site Please see Brief Summary of Prescribing Information on adjacent page.